Clinical Trials Logo

Clinical Trial Summary

DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time [PT] and activated partial thromboplastin time [aPTT]) from plasma samples show a high variation. Special coagulation tests like hemoclot for dabigatran and chromogenic substrate assays for Rivaroxaban, Apixaban, and Edoxaban are time-consuming and can be performed only in specialized laboratories. In specific medical situations like in patients such as emergency procedures, stroke (before starting thrombolytic therapy), trauma, general surgery or other invasive procedures, it may be necessary for medical decision making to know the presence or absence of a DOAC in patient's body fluid. Until now there is no rapid, specific and sensitive coagulation test available in the market.


Clinical Trial Description

This prospective, open-label, controlled, not randomized trial in healthy volunteers to investigate comparatively the pharmacokinetics of the direct oral anticoagulants in plasma and in urine with LC-MS/MS and in urine by DOAC Dipstick. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05491460
Study type Interventional
Source Doasense GmbH
Contact
Status Active, not recruiting
Phase Phase 1
Start date July 1, 2022
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05361889 - ReAl-life multIceNter Outcomes Registry for Better antithrOmbotic Strategies in Patients With AF (RAINBOW-AF)
Completed NCT03143569 - Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial N/A
Recruiting NCT05486351 - Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
Completed NCT04623177 - Thromboprophylaxis for Patients in ICU With COVID-19
Withdrawn NCT01541098 - A Clinical Study of Lyophilized Plasma in Patients on Warfarin Phase 2
Completed NCT04351438 - Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation
Recruiting NCT05181774 - Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics
Completed NCT03182829 - In Vitro Diagnostic Test for DOAC in Urine